Abstract Details

Title Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy

Topic Child Neurology and Developmental Neurology

Presentation(s) S46 - (-)

Poster/Presentation
Number 003

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Darryl C. De Vivo, MD, FAAN (Columbia University) PRESENTER	Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen and Novartis. Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aspa Therapeutics.
	No disclosure on file
Sandra P. Reyna, MD	Dr. Reyna has received personal compensation for serving as an employee of Novartis Gene Therapies.
Wildon Farwell, MD	Dr. Farwell has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Farwell has received personal compensation for serving as an employee of Satellos Biosciences. Dr. Farwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Paragon Therapeutics. Dr. Farwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Farwell has stock in Dyne Therapeutics. Dr. Farwell has stock in Satellos Bioscience.
Sarah Gheuens, MD	No disclosure on file
	No disclosure on file
John Zhong	No disclosure on file
	No disclosure on file
Erica Selheimer, MD	No disclosure on file
Enrico S. Bertini, MD (Bambino Gesu Hospital)	Dr. Bertini has received personal compensation for serving as an employee of Bambino Gesu' Children's Resesarch Hospital.
	No disclosure on file

��ɫ��